Scailyte

We are devoted to making single-cell technology available for every lab. Scipio bioscience is a French biotech startup developing, manufacturing and selling laboratory kits and analysis software for single-cell RNA sequencing (scRNA-seq). Our goal is to enable all life-science researchers to easily access this new single-cell technology by breaking down the technical, logistical, and financial barriers through scientific innovation for novel insights and discoveries. Vivien joined Scipio in July 2021 to set up DevOps practices and lead the way into Cloud technology for Cytonaut. At Scipio we are passionate about empowering every researchers to discover the molecular mechanisms of life for a better health and sustainable world. We are here to support you and bring your project to life. Single-cell sequencing is a most promising technology which greatly enhances possibilities of existing bulk genomic sequencing. Marie-Claude comes with a vast experience in different environments from start-ups to leading large teams in public corporations like QIAGEN around the globe.

Through its proprietary Cell-Seq platform technology, Scenic has built a strong intellectual property portfolio covering its therapeutic targets and its chemistry. Philippe has fulfilled leading roles in multiple biotech and medtech companies, including Themis Bioscience (acquired by Merck), GlycoVaxyn (acquired by GSK), Endoart (acquired by Allergan) and Axovan (acquired by Actelion). Simone is a Partner at Inkef and brings with him 20 years of experience across venture capital and startup creation. Stephen is a visionary leader in Genetics, Cancer, and Digital Health. Ton is a world-leading expert in Immuno Oncology.

Read how companies around the globe are switching to Scilife. Join our epic team and climb on board the Scilife rocket! Get to know us better and learn what binds us at Scilife. At Scilife, we help people and organizations transform quality into a catalyst for value creation, making Smart Quality a culture. The 10th of May of 2017 marked the start of an amazing journey: Scilife was officially established!

SciCalQ, established in 2017, is a tech-based company providing AI solutions & computational chemistry services to academic or industrial organizations. We are formed by a group of enthusiastic young people who have professional backgrounds in computational chemistry and machine learning, and committed to making drug discovery more intelligent. Now, as a pioneer, SciCalQ is ready to provide the best products and services to clients all over the world. SciCalQ provides advanced Artificial Intelligence (AI) and Computational Chemistry (CC) solutions to accelerate the process of new drug discovery and design. Your best choice in AI drug dicovery and computational chemistry solutions provider. We mainly focus on the artificial intelligence (AI) solutions in drug discovery, including the physical property predictions for lead compounds, ranking in drug repurposing, molecular dynamic (MD) simulations for large systems, etc.

Our Scigilian Discovery Platform’s life science solutions help the world’s leading pharmaceutical companies bring their vision to life – empowering them to discover and develop medicines by focusing on linking scientific knowledge with unique medical innovations. Scigilian is a leading life science solutions provider specializing in solutions that address the collaboration challenges of a distributed lab research environment. With Scigilian, you can easily adapt to new methods and process changes, see a complete overview of samples that are queued and their status, and so much more! Not sure how Scigilian can help transform the way you manage your lab? Scigilian centralizes your information in one place, allowing you to streamline lab operations, boost efficiency, avoid data loss, and share knowledge in real-time, so you can quickly innovate and advance your discovery efforts. Scigilian is everything you need to efficiently enable data-driven decisions and streamline the knowledge flow between your research teams. Brings 30+ years of experience delivering effective IT solutions to the challenges facing the life sciences industry. Jerry Ferentinos, CTO, has been delivering valuable and effective IT solutions to pharmaceutical R&D challenges for over 25 years.

ScopeSys is a Canadian company with a mission to help translate the value of our unique single-molecule imaging platform to real-world applications, such as the advancement of new medicines, and offers career opportunities to young Canadian biophysicists and bioengineers. ScopeSys has also placed early-access technology packages in the labs of select researchers to pursue a range of applications. Sabrina is founder of ScopeSys and lead inventor of the CLiC technology. First as a ScopeSys Mitacs Post Doc and subsequently as Analytics Lead at ScopeSys. Joining ScopeSys in June 2023 as an NMIN post-doc and as a MITACS Postdoctoral fellow in November 2023, Ariadne specializes in understanding the biophysics of mRNA-LNPs at high resolution, as well as CLiC microscopy. ScopeSys is a commercial-stage developer of disruptive technologies for single-molecule imaging with applications in genomic-medicine drug development. ScopeSys’ Convex Lens-induced Confinement (CLiC) technology enables high-throughput measurements with single-molecule resolution. Andree is the lead instrumentation and software engineer at ScopeSys.